

A Narrative Review of the Role of Immunotherapy in Metastatic Carcinoma of the Colon Harboring a BRAF Mutation

ALFREDO COLOMBO¹, PORRETTO MARIA CONCETTA¹, VITTORIO GEBBIA^{2,3},
DANIELA SAMBATARO^{2,4}, GIUSEPPINA SCANDURRA^{2,5} and MARIA ROSARIA VALERIO⁶

¹Medical Oncology Unit, CdC Macchiarella, Palermo, Italy;

²Medical Oncology, Department of Medicine and Surgery, Kore University of Enna, Enna, Italy;

³Medical Oncology Unit, CdC Torina, Palermo, Italy;

⁴Medical Oncology Unit, Ospedale Umberto I, Enna, Italy;

⁵Medical Oncology Unit, Ospedale Cannizzario, Catania, Italy;

⁶Medical Oncology Unit, Policlinico, University of Palermo, Palermo, Italy

Abstract. Patients affected by metastatic carcinoma of the colon/rectum (mCRC) harboring mutations in the BRAF gene (MBRAF) respond poorly to conventional therapy and have a prognosis worse than that of patients without mutations. Despite the promising outcomes of targeted therapy utilizing multi-targeted inhibition of the mitogen-activated protein kinase (MAPK) signaling system, the therapeutic efficacy, especially for the microsatellite stable/DNA proficient mismatch repair (MSS/PMMR) subtype, remains inadequate. Patients with MBRAF/mCRC and high microsatellite instability or DNA deficient mismatch repair (MSI-H/DMMR) exhibit a substantial tumor mutation burden, suggesting a high probability of response to immunotherapy. It is widely acknowledged that MSS/pMMR/mCRC is an immunologically "cold" malignancy that exhibits resistance to immunotherapy. The integration of targeted therapy and immunotherapy may enhance clinical

outcomes in patients with MBRAF/mCRC. Efforts to enhance outcomes are exclusively focused on MSS/DMMR-BRAF mutant cancers, which constitute the largest proportion. This review evaluates the clinical efficacy and advancement of novel immune checkpoint blockade therapies for MSI-H/DMMR and MSS/PMMR BRAF mutant mCRC. We examine potential indicators in the tumor immune milieu for forecasting immunotherapeutic response in BRAF mutant mCRC.

Colorectal cancer (CRC) ranks as the third most common malignancy globally and the second most lethal cancer (1). The increase in the incidence of CRC in younger patients registered in the last decades may be linked to familial, genetic, habits, alimentary, and environmental factors (2). Despite the efficacy of screening programs in diminishing mortality and morbidity associated with CRC, 20-35% of patients are first diagnosed with metastatic colorectal cancer (mCRC), which has a five-year overall survival (OS) rate of approximately 13% (3-5). In this setting, molecular profiling plays a pivotal role. The NCCN guidelines strongly support the performance of genetic analysis before starting treatment, including mutation of K- and NRAS, BRAF, and mismatch repair (MMR) genes (6). Wild-type RAS (wRAS) mCRC represent 40-45% of cases, while high microsatellite instability/DNA deficient mismatch repair (MSI/DMRR) represent approximately 4% of metastatic CRC. Only 12% of mCRC have a mutation in the codon 600 of the BRAF gene (MBRAF), i.e., the V600E, in which glutamine substitutes for valine (7, 8). Mutated BRAF mCRC cases have a median OS shorter than 15 months (9).

Even today, chemotherapy (CT) alone or in combination with targeted agents is the therapeutic cornerstone for mCRC.

Correspondence to: Dr. Vittorio Gebbia, Chair of Medical Oncology, Department of Medicine and Surgery, Kore University of Enna, Contrada Santa Panasia, 94100, Enna, Italy. E-mail: vittorio.gebbia@unikore.it

Key Words: Colon cancer, mutations, immunotherapy, BRAF, microsatellite instability, review.

©2025 The Author(s). Published by the International Institute of Anticancer Research.



This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

The FOLFOXIRI regimen, a combination of fluorouracil, leucovorin, oxaliplatin, and irinotecan with or without bevacizumab (BEV), is the recommended first-line therapy for fit patients with MBRAF/mCRC (10). Alternatively, a doublet regimen of CT plus BEV may be used if toxicity is a concern. However, progression-free survival (PFS) and median OS are far from being satisfactory (11).

Unlike other neoplasms, patients with MBRAF/mCRC do not benefit from single-agent BRAF inhibitors because of the intracellular activation of PI3K/Akt and Wnt/ β signaling pathways, which support the development of resistance (8, 12-17).

In pretreated MBRAF/mCRC, the combination of targeted medicines, including BRAF and EGFR inhibitors, had favorable outcomes (18-20). Encorafenib (ENC) in conjunction with cetuximab (CET) enhanced the objective overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in previously treated patients with metastatic colorectal cancer (mCRC) compared to irinotecan-CET based chemotherapy. Notwithstanding the intriguing clinical efficacy, the combination of ENC, binimetinib, and CET (ANCHOR study) yielded inferior outcomes compared to CT in first-line MBRAF/mCRC treatment (21). Immune checkpoint inhibitors (ICIs) activate the immune system eliciting a potent anticancer effect and have also been tested in mCRC (22, 23). ICIs employed in clinical practice are monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 and programmed cell death 1 receptor (PD-1), approved for the treatment of several malignancies (23). ICIs have significant activity in mCRC with high microsatellite instability (MSI-H) and a high cancer mutation burden (24). mCRC commonly displays BRAF mutations associated with MSI-H (30%) or DNA deficient mismatch repair (dMMR) (25). ICIs have recently been shown to achieve extended responses in patients with mCRC and high microsatellite instability/DNA deficient mismatch repair (MSI-H/dMMR) (26). However, ICI monotherapy is not very effective in MBRAF/mCRC with microsatellite stability/DNA proficient mismatch repair (MSS/PMR) (27). In such setting, ICIs are being investigated in combination with other anticancer drugs, including BRAF inhibitors (28). This narrative review addresses the immunological microenvironment and the role of ICIs in BRAF-mutated metastatic CRC.

Pathogenesis of BRAF-mutant mCRC

The several diverse mechanisms leading to the development of CRC include the serrated and traditional adenoma-carcinoma routes, as shown in Figure 1 (29). Many serrated premalignant lesions result from precocious *BRAF* mutations (30, 31). BRAF is fundamental for tumor proliferation, differentiation, angiogenesis, apoptosis, and metastatic diffusion (32). Mutated BRAF kinase is constitutively phosphorylated, inducing the

prolonged stimulation of MAPK pathway leading to cancer growth (12, 33). Metastatic CRC is often correlated with *BRAF* mutations, especially the BRAF V600E variant, which may be associated with the hypermethylation of the MLH1 promoter and the CpG island. Biomolecular investigations facilitated the categorization of MBRAF CRC into three classes: class I endowed with elevated kinase activity (V600 mutation), class II with non-V600 alterations, and class III characterized by insufficient kinase activity (33-37). The serrated pathway is strongly correlated to class I, which is the most frequent and the worst prognostically, while class III CRCs are likely to have a prognosis close to that of wCRC (37). Three distinct molecular mechanisms are responsible for CRC: microsatellite instability (MSI), chromosomal instability (CIN), and the CpG (cytosine preceding guanine) pathway of methylation phenotype (CIMP) (38, 39). The microsatellites are part of a broad class of 1-6 kb DNA motifs that have significant levels of sequence variation that are present in all genomes (40). The dMMR status, which is primarily seen at microsatellites, results in many mutations or gene silence (41, 42). BRAF mutations are seen in less than 10% of MSS/mCRC cases (25, 35, 43). Classification of MBRAF/CRC may predict best treatment for patients (44). Molecular subtypes consensus (CMS) reported 70% of MBRAF/CRC belonging to the MSI immune-group (CMS1), which has higher number of immunologic cells and best OS (45, 46). Moreover, approximately 15% of MBRAF/mCRC are CMS4 (47). Moreover, genetic profiling differentiates some subtypes of BRAF V600E mutation, independently of sex, tumor side, and MSI or PI3K status (48). BRAF V600E Mutation 1 (BM1) has an overall more robust immunological profile than BRAF V600E Mutation 2 (BM2) mediated by pathways including the stimulation of IL2/STAT5, TNF α , IL6/JAK/STAT3 pathways, and allograft rejection. Patients with BM1 receiving EGFR inhibitors had better ORR, median PFS, and median OS than BM2 ones (49).

Immune Checkpoint Inhibitors in MBRAF/mCRC

MSI-H/dMMR subgroup. The use of ICIs in MSI-H/mCRC has led to considerable progress. The Keynote 164 phase II trial (NCT02460198) studied the PD-1 inhibitor pembrolizumab in previously untreated patients with MSI-H/dMMR mCRC. Single-agent pembrolizumab induced an 25% and 55% ORR in patients with MBRAF already treated with 1 or 2 lines of CT, respectively (50). The phase II multicenter, open-label Checkmate 142 trial (NCT02060188) is currently investigating nivolumab (NIV), another PD-1 inhibitor, alone or in combination with the CTLA-4 inhibitor ipilimumab. The investigator-assessed ORR was 31.1% [95% confidence interval (CI)=20.8-42.9%] in 74 patients with MSI-H/mCRC who had undergone prior treatment with at least one regimen, whereas the ORR in the metastatic BRAF cohort was 25% (51). In a separate trial, the combination of NIV with low-dose




Figure 1. Pathways of colorectal carcinogenesis. Activation of the Wnt pathway (primarily via APC mutation) or a mutation in BRAF can initiate colorectal tumorigenesis. BRAF mutations promote tumorigenesis via the serrated neoplasia pathway, leading to MSI with or without hypermutation (indicated in the Figure). Colorectal tumor classifications include CIN, MSI, and the serrated pathway (see CMS). L: Low; H: high; EMT: epithelial to mesenchymal transition (reproduced with permission from Elsevier through Copyright Clearance Center's RightsLink® service).

ipilimumab (IPI) produced an ORR of 65% (95%CI=55-73%) and a disease control rate (DCR) of 81% (95%CI=72-87%) in previously treated patients (52). The overall response rate (ORR) was 70% in patients with MBRAF/mCRC, accompanied by a tolerable safety profile (52). No statistically significant difference was seen in the ORR with ICI between wild type and MBRAF/mCRC with MSI-H/dMMR (OR=1.04; 95%CI=0.48-2.25), despite the possibility that ICIs could provide MBRAF/mCRC patients with MSI-H/dMMR with a potential clinical response advantage in subsequent lines of therapy (9). The Checkmate 142 trial tested NIV in combination with a low-dose IPI regimen as first-line therapy achieving a 76.5% 24-month PFS rate and 76% investigator-assessed ORR in patients with MBRAF/CRC (53). The Keynote 177 phase III study compared single-agent pembrolizumab (PEM) to CT in treatment-naïve, patients with MSI-H/dMMR mCRC (26, 54). Although results showed no difference in median OS between the study arms (HR=0.74, 95%CI=0.53-1.03, $p=0.036$), the final analysis reported a significant prolongation in median PFS in favor of PEM (16.5 vs. 8.2 months; HR=0.59, 95%CI=0.45-0.79, $p=0.0002$). A subgroup analysis of MBRAF V600E cases showed lack of OS benefit (HR=0.72, 95%CI=0.35-1.47) even though there was a statistically significant difference in PFS (HR=0.48, 95%CI=0.27-0.86). With 60% of patients getting anti-PD-1 or anti-PD-L1 therapy following first-line CT, the lack of appreciable OS benefit could be related to the crossover design of the study. However, PEM improved the health-related quality of life (HRQOL) with fewer adverse events (54, 55). In the group of patients with MSI-H/dMMR mCRC, there was

no difference in clinical benefit between the MBRAF and the non-MBRAV subgroups. The effectiveness of ICIs with conventional therapies in the subset of patients with MBRAF/mCRC should be compared in direct prospective trials. However, a recent real-world retrospective investigation reported a negative impact of the BRAF V600E mutation on the response to ICIs in MSI-H/mCRC (56). Patients with MBRAF/CRC and those with wild type showed a 44.4% vs. 74.2% ORR respectively, without a statistically significant difference ($p=0.120$) and shorter 12- and 24-month PFS rates than those of BRAF wild-type patients (12-months PFS rate of 40.0% vs. 73.3%, $p<0.001$; 24-months PFS rate 26.7% vs. 73.3%, $p<0.001$). Still, there were few BRAF V600E individuals in this subgroup analysis, and the treatment timing was unclear. A fraction of MSI-H/dMMR mCRC have a de novo or acquire resistance to ICIs showing no response to treatment.

New biomarkers to assess potential responders among patient populations and feasible treatment strategies require more research. Strategies for combined therapy have been proposed to address immunotherapy resistance. The phase III SEAMARK study is currently ongoing with the aim of comparing pembrolizumab as single agent or in combination with the EGFR inhibitor CET and the BRAF inhibitor ENC as the first-line treatment of MBRAF/mCRC with MSI-H/dMMR. In conclusion, ICIs may achieve long-lasting responses and improve prognosis, although some patients are refractory to therapy. The CA209-8HW trial randomized previously untreated patients to receive NIV-IPI (202 patients) or chemotherapy (101 patients) as first-line therapy. Of these

patients, 171 patients in the NIV-IPI arm and 84 patients in the CT arm had centrally confirmed MSI-H/dMMR. With 24.3 months of median follow-up, immunotherapy demonstrated clinically meaningful and statistically significant improvement in PFS *versus* CT, with a 79% reduction in the risk of disease progression or death [HR=0.21 (95%CI=0.14-0.32); $p<0.0001$]. These results support first-line NIV-IPI as a standard-of-care option for patients with MSI-H/dMMR mCRC (57).

MSS subgroup. While treating MSS/PMMR mCRC with ICI alone demonstrated less benefit, the Keynote 016 trial revealed a substantial advancement in creating an immunological therapy strategy for MSI-H/dMMR mCRC (5, 27, 58, 59). Intrinsic resistance renders patients with MSS/PMMR mCRC resistant to single-agent ICI (60). Nevertheless, combination therapies, including ICIs, still need to be investigated further for MSS/PMMR mCRC, selecting pertinent patient populations with predictive biomarkers and overcoming intrinsic resistance, particularly for patients with MBRAF who have poor prognoses and no satisfying therapy options.

ICI plus anti-VEGF agents. Angiogenesis is an essential step in solid tumor growth. Cancers with the BRAF V600E mutation have a significant increase in proangiogenic factors (61). In the neoplastic tissue, aberrant and leaky blood vessels emerge because of the angiogenic vascular endothelial growth factor (VEGF) (62). Preclinical research suggests that VEGF may directly influence immune cells, such as regulatory T cells, dendritic cells, tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells, all of which have been shown to exert immunosuppressive effects (63, 64). Therefore, inhibiting the VEGF signaling pathway may increase the efficacy of ICIs by normalizing the tumor vasculature and altering the immune environment.

There are currently few study data on patients with MBRAF/mCRC. In patients with MSS gastrointestinal malignancies, the phase Ib/II REGONIVO trial examined the safety and effectiveness of NIV plus the VEGFR2 inhibitor regorafenib, a multikinase inhibitor (65). The 25 patients in the MSS/PMMR mCRC cohort had a median PFS of 7.5 months and an ORR of 36%. The phase II NIVACOR study examined the efficacy of the FOLFOXIRI regimen in combination with BEV and NIV in 52 mCRC patients with a mutation in the RAS/BRAF gene (66). With a median duration of 7.59 (95%CI=6.21-11.43) months, the ORR was 78.9%. The median PFS and DCR for the MSS patient subgroup were 9.8 (95%CI=8.18-15.24) months and 96.2%, respectively. The outcome for patients with MBRAF/mCRC remains uncertain. In the meantime, a case report revealed that an MSS/PMMR mCRC patient with MBRAF had a PFS of more than 17 months when treated with the combination NIV and BEV (67).

ICIs in addition to MAPK pathway-blocking drugs. Immunotherapy may be aided by changing the tumor microenvironment, immune cell ratio, and MAPK pathway inhibition, according to growing research (68). In MBRAF metastatic melanoma, ICIs in conjunction with inhibitors of the MAPK pathway are effective (69-72). Research on these combinations has also been carried out in MBRAF/mCRC. In 73 patients with MBRAF/mCRC, a phase II trial evaluated patients with BRAF V600E mutant mCRC treated with the BRAF inhibitor dabrafenib in addition to the MEK inhibitors trametinib and spartalizumab (73, 74). The DCR was 70.3%, and the ORR was 24.3%. The median PFS of the 28 patients with MSS/mCRC who had not received prior treatment was 5.6 months, and the ORR and DCR were 25% (7/28) and 75% (21/28), respectively. A comparison between the combination of the PD-1 inhibitor and the dabrafenib plus trametinib treatment shown good efficacy (75). Following therapy, T cells and other immune cell types invaded tumor biopsies more heavily than in pre-treatment biopsies (73).

In patients with MSS and MBRAF/mCRC, a phase I/II trial assessed the dose, safety, and effectiveness of ENC when combined with CET and NIV (76). The trial is still actively recruiting, and the results showed an extraordinarily high ORR of 96% (95%CI=78-100%) and 48% (95%CI=27-69%). The average response time was 7.7 months (95%CI=4.5-NA). Notably, compared to targeted treatment, the median PFS and OS were 7.4 months (95%CI=7.7-NA) and 15.1 months (95%CI=5.6-NA), respectively, indicating greater efficacy. Patients tolerated the combination treatment well in terms of safety profile; just 19% (5/26) experienced grade 3 or 4 adverse events. A second randomized phase II trial (NCT05308446) investigates the advantages of combining NIV with CET and ENC in patients with BRAF V600E mutation-positive MSS mCRC who have already received treatment. In conclusion, the modest clinical trial implies that the combination of ICIs and MAPK inhibition may be beneficial for individuals with BRAF-mutated MSS/PMMR mCRC (77).

New Immunotherapy Response Biomarkers

Immune system cells. The tumor microenvironment (TME) is a dynamic system of many cell types, such as fibroblasts, stromal cells, immune cells, and extracellular matrix. This important factor affects how well immunotherapy works (78, 79). The development of tumors and their resistance to immune therapy depend on the immune microenvironment of a tumor (TIME), which is made up of immune cells, such as CD8+T cells, CD4+T cells, myeloid-derived suppressor cells (MDSCs), anti-inflammatory macrophages, natural killer (NK) cells, and related non-cellular components (80). It is imperative to comprehend the characteristics of TIME and effectively handle the involvement of immunosuppressive factors in TME to improve ICI efficacy in patients with mBRA/mCRC.

Tumor-infiltrating lymphocytes (TILs). TILs including CD8+ cytotoxic T cells, CD4+ helper T cells, regulatory T cells, and B cells, are pivotal for the antineoplastic immune response (81, 82). Intra-tumoral TIL density may be a predictive marker for clinical outcome and response to ICI in a range of malignancies (81-83). Unluckily, no solid data on TIL density's predictive ability to evaluate ICI's effectiveness in MBRAF/mCRC are available. However, regardless of the presence of a *BRAF* mutation, a larger density of TILs was associated with a better prognosis (84, 85). Information on TIL density in MBRAF CRC is limited and somehow contradictory (86-88). A study including 24 patients with MBRAF/mCRC showed that *BRAF* mutation status was not significantly linked to the density of CD8+ (86). A different study found that the number of CD8+, CD3+, and FOXP3+ regulatory T cells was not substantially connected with *BRAF* mutation (87), while CD45RO+ T cells were more significant in 114 patients with MBRAF/mCRC ($p=0.0006$). When anti-PD1 therapy is used, TIL density around the periphery of tumor infiltration has been more strongly associated with anti-PD1 response than TIL density in the center of infiltration. The infiltrative borders of MBRAF/mCRC specimens exhibited a much higher density of FOXP3+ T cells compared to the core, which displayed lower densities of CD4+ and FOXP3+ T cells ($p<0.001$) (88).

Cen *et al.* conducted a thorough evaluation of the immunological milieu in MBRAF/mCRC (89). The expression of CD8+ T lymphocytes was significantly elevated in 43 patients with MBRAF/mCRC compared to patients WBRAF ($p<0.001$) (89). The proportion of CD8+ T cells was markedly elevated ($p<0.01$) in MBRAF/CRC tissues compared to WBRAF tissues, based on data from The Cancer Genome Atlas (TCGA) datasets, which comprised 59 patients with MBRAF and 337 patients with WBRAF (89). In contrast, the percentage of CD8+ T cells exhibited no significant differences between groups as per the Gene Expression Omnibus (GEO) datasets (89). CRCs with a *BRAF* mutation exhibit diminished tumor purity ($p=0.0003$), an elevated stromal score ($p=0.02$), a heightened immunological score ($p<0.0001$), and an increased ESTIMATE score ($p=0.0001$) compared to non-mutated counterparts. The assessment of TIL levels may be inadequate to fully delineate the intricate dynamics of *BRAF* mutant colorectal cancer. Consequently, this matter requires reevaluation, considering other factors, including CMS categorization and MSI status. Digiacomo *et al.* evaluated the tumor-infiltrating lymphocytes (TILs) in 22 microsatellite instability (MSI) and 37 microsatellites stable (MSS) metastatic *BRAF*-mutant colorectal cancer (MBRAF/mCRC) cases, revealing differences in TILs among various disease subtypes (90). The findings demonstrated that CD8+ and CD3+ lymphocytes, intra-tumoral lymphatic invasion (ILI), and peritumoral lymphatic invasion (PLI) were significantly more common in MSI tumors compared to MSS

tumors (CD8, $p=0.0001$ and $p<0.0001$; CD3, $p=0.003$ and $p=0.0003$; ILI and PLI, respectively). Class 2 MBRAF/mCRC cases exhibited a higher infiltration of CD3+ and CD8+ lymphocytes compared to class 3 ($p=0.033$) (34).

Tumor-associated macrophages (TAMs). TAMs are an important component of the TME, contributing to tumor immunosuppression, development, invasion, metastasis, angiogenesis, and drug resistance through interactions with other immune cells (91). This population comprises M1 and M2 macrophages (MAC). M1 macrophages are classically activated, typically by lipopolysaccharides or IFN- γ , and are involved in producing proinflammatory cytokines, phagocytosing microbes, and initiating immune responses. The latter, however, produce reactive oxygen intermediates or nitric oxide to combat bacteria and viruses. M2 macrophages are alternatively activated by cytokines like IL-4, IL-10, or IL-13 and play a role in tissue repair and immune regulation. M2 macrophages can produce either proline to stimulate collagen synthesis or polyamines to promote cell proliferation. M1 MAC have an anticancer and proinflammatory effect, while M2 MAC may affect immunosuppression and cancer behavior (92). Initially recognized as M2-like MAC, TAMs were unreliable predictors of different cancer outcomes (92). There is limited data in the medical literature regarding the function of macrophages in MBRAF/mCRC. However, one study found that CD163+ M2 macrophages were significantly more abundant in MBRAF/mCRC tumors compared to wild-type tumors (mean 5.93 ± 3.02 vs. 3.67 ± 3.02 , respectively, $p=0.040$) (93-95). In contrast, CD68+ M1 MAC levels were not different between wild-type and MBRAF patients (mean $\pm$ SD, 18.43 ± 13.53 vs. 20.96 ± 15.34 , respectively, $p=0.664$). Additionally, patients with MBRAF have more M1 MAC than patients with WBRAF ($p<0.05$). However, a study that included 110 patients with MBRAF CRC and 798 patients with WBRAF CRC from the TCGA and the GEO datasets revealed no significant variations in M2 MAC between these groups (89). In another investigation, considering a subgroup of patients with unresectable mCRC based on *BRAF* status, high tumor infiltration by CD68+ MAC had no prognostic value for MBRAF/mCRC (92). However, WBRAF/mCRC patients with more tumor infiltration by CD68+ MAC had a better median OS ($p=0.002$) (92). Further studies are needed to clarify the features of TAMs in this subgroup of CRC and their impact on immunotherapy and prognosis (95).

PD-L1 expression. The transmembrane protein PD-L1, sometimes referred to as CD274 or B7 homolog 1 (B7-H1), is a membrane protein in cancer cells that inhibits the immune system by binding to PD-1 on T cells, facilitating escape from immunosuppression. ICIs targeting PD-L1, or PD-1 demonstrate efficacy in several malignancies outside CRC. Patients with CRC exhibit PD-L1 expression in approximately

9-15% of instances, and this expression serves as a predictor for responsiveness to ICIs, even though anti-PD-1/PD-L1 therapy proves unsuccessful for several patients with mCRC (96-98). The MSI-H status forecasts the effectiveness of ICI therapy in mCRC (58). Notably, MSI colon cancer exhibited elevated PD-L1 expression levels compared to the MSS cohort (99-101). Consequently, PD-L1 expression may serve as a significant biomarker for forecasting the efficacy of ICIs in mCRC.

Certain characteristics of serrated carcinoma, including poor differentiation, solid/medullary histology, MSI-H or DMMR, and BRAF mutation, are associated with the activation of PD-L1 (100, 102-104). Cen et al. indicated that 43 patients with MBRAF/mCRC exhibited markedly elevated expression levels of PD-L1, PD-1, CTLA4, and LAG3 (89). The V600 mutation is associated with elevated PD-L1 expression in MSS/CRC cell lines, indicating a linkage between BRAF mutation and PD-L1 expression. This indicates that PD-L1 expression is not limited to MSI-H, MBRAF CRC. Despite the absence of evidence for the MBRAF patient subset, a definitive association between PD-L1 expression and the efficacy of ICIs is lacking (51, 52). Additional immune-independent roles of PD-L1 expression in MBRAF/mCRC are present. Feng et al. demonstrated that the oncogenic BRAF V600E mutation can transcriptionally enhance intrinsic PD-L1 expression in colon cancers, hence improving CT-induced apoptosis through the up-regulation of BIM and BIK proteins (105, 106). They also showed that the c-JUN and YAP genes enhance PD-L1 expression in MBRAF/CRC (106).

Tertiary Lymphoid Structures (TLS)

Tertiary lymphoid structures (TLS) occur mainly in infectious diseases, inflammatory disorders, autoimmune syndromes, as well as tumors (107). As a part of the tumor microenvironment, TLS play a role in the growth and dissemination of malignancies (108). TLS may also be a predictive biomarker for ICI activity and a prognostic biomarker for human cancers (107, 108). Posch *et al.* reported that CRC with BRAF and MSI-H mutations is linked to greater TLS density (median: 0.61 vs. 0.45, $p=0.03$). TLS is primarily seen in the periphery of CRC tumor tissues (97%) (109).

Overall, several CRC clinical trials, including limited numbers of patients, have suggested that additional immunotherapeutic biomarkers, aside from MSI, are also connected with patient survival and ICI efficacy. As such, these findings require confirmation in larger investigations.

Conclusion

Patients with MBRAF/mCRC exhibit a limited response to standard treatment, resulting in a bleak prognosis (110). Patients

with mCRC exhibiting BRAF V600E mutations may derive benefits from a combination of a BRAF inhibitor and an EGFR inhibitor $\pm$ MEK inhibitor; nonetheless, the overall response rate (ORR) is approximately 20%, but improved outcomes may occur in those with MSS and RNF43 mutations (18, 111).

ICI has achieved sustained responses in patients with MSI-H/DMMR mCRC. Subgroup analysis of clinical studies indicates a benefit for MSI-H patients with MBRAF/mCRC, while additional confirming data is required. Nonetheless, not all patients with MSI-H/DMMR exhibit a response to ICIs. A meta-analysis of 16 trials including 1503 patients with CRC showed a 42% ORR in the MBRAF and 19% in the RAS mutant group. The ORR was 14% in the PD-L1 positive subgroup and 32% in the PD-L1 negative subgroup suggesting that low expression of PD-L1 can be potential predictive marker for positive response and outcome (112).

Given that mBRAf/mCRC is a heterogeneous tumor subtype with diverse responses to ICI, additional studies into supplementary predictive biomarkers for identifying immunotherapy-sensitive patients beyond MSI-H is warranted. Patients with MSS/PMMR mCRC exhibit no response to ICIs when used alone. In the Enco-CTX-Nivo and Dabra-Tram-Sparta studies, ICIs appear to enhance the efficacy of BRAF inhibitors. Notable data have been documented with immunotherapy and MAPK pathway inhibition in mBRAf/mCRC patients with MSS/PMMR; nevertheless, confirmatory phase III clinical trials are necessary. Moreover, certain combinatorial therapies, including ICIs with radiation, CT, and tumor vaccines, may enhance the host immune response and surmount resistance to singular targeted therapies. Although MSI appears to mitigate the unfavorable prognosis associated with BRAF mutation, other biomarkers are necessary to enhance patient selection and create more precise biomarkers. The plasmatic BRAF-V600E allelic fraction holds prognostic relevance in mCRC undergoing anti-BRAF combinatorial therapies, effectively identifying individuals likely to benefit from ENC plus CET (113, 114). Ultimately, enhanced outcomes may be achieved by integrating BRAF inhibitors with Wnt pathway inhibitors and ICIs. Newer studies focused on other potential diagnostic and prognostic biomarkers. Collagen triple helix repeat containing 1 (CTHRC1), which may act as a negative regulator of collagen matrix deposition, may have potential use in CRC. A high expression of CTHRC1 was associated with mBRAf and with poor prognosis and worse clinicopathological features and with decreased sensitivity to anti-MBRAf drugs (115).

In conclusion although remarkable progresses have been achieved in the last decade, further studies and confirming phase III trials are required.

Conflicts of Interest

The Authors declare no conflicts of interest in relation to this study.

Authors' Contributions

All Authors contributed to the medical literature search and evaluation. AC and VG wrote the manuscript draft and edited it. All Authors read and approved the final version of the manuscript.

Funding

This research received no external funding.

References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 71(3): 209-249, 2021. DOI: 10.3322/caac.21660
- Brenner H, Stock C, Hoffmeister M: Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. *BMJ* 348: g2467, 2014. DOI: 10.1136/bmj.g2467
- Jin H, Amonkar M, Aguiar-ibáñez R, Thosar M, Chase M, Keeping S: Systematic literature review and network meta-analysis of pembrolizumab *versus* other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC. *Future Oncol* 18(17): 2155-2171, 2022. DOI: 10.2217/fon-2021-1633
- Piawah S, Venook AP: Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. *Cancer* 125(23): 4139-4147, 2019. DOI: 10.1002/cncr.32163
- O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul Razak AR, Dotti K, Santoro A, Cohen RB, Gould M, Saraf S, Stein K, Han SW: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. *PLoS One* 12(12): e0189848, 2017. DOI: 10.1371/journal.pone.0189848
- Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F: Colon Cancer, Version 3.2024, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 22(2D): e240029, 2024. DOI: 10.6004/jncn.2024.0029
- Yukimoto R, Nishida N, Hata T, Fujino S, Ogino T, Miyoshi N, Takahashi H, Uemura M, Satoh T, Hirofumi Y, Mizushima T, Doki Y, Eguchi H: Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer. *Cancer Sci* 112(7): 2884-2894, 2021. DOI: 10.1111/cas.14929
- Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L: Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. *J Clin Oncol* 33(34): 4032-4038, 2015. DOI: 10.1200/JCO.2015.63.2497
- Park R, Lopes L, Lee S, Riano I, Saeed A: The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. *Future Oncol* 17(31): 4221-4231, 2021. DOI: 10.2217/fon-2021-0552
- Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, Masi G, Ongaro E, Hurwitz H, Falcone A, Schmoll HJ, Di Maio M: Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab *versus* doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. *J Clin Oncol*: JCO2001225, 2020. DOI: 10.1200/JCO.20.01225
- Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A: FOLFOXIRI plus bevacizumab *versus* FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. *Lancet Oncol* 16(13): 1306-1315, 2015. DOI: 10.1016/S1470-2045(15)00122-9
- Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. *Cancer Discov* 2(3): 227-235, 2012. DOI: 10.1158/2159-8290.CD-11-0341
- Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. *Clin Cancer Res* 19(10): 2688-2698, 2013. DOI: 10.1158/1078-0432.CCR-12-2556
- Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S: Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. *Clin Cancer Res* 19(3): 657-667, 2013. DOI: 10.1158/1078-0432.CCR-11-1446
- Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G: Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. *Cancer Res* 72(4): 969-978, 2012. DOI: 10.1158/0008-5472.CAN-11-1875
- Chen G, Gao C, Gao X, Zhang DH, Kuan SF, Burns TF, Hu J: Wnt/ β -catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer. *Mol Cancer Ther* 17(4): 806-813, 2018. DOI: 10.1158/1535-7163.MCT-17-0561
- Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R: Unresponsiveness of colon cancer to BRAF(V600E) inhibition

- through feedback activation of EGFR. *Nature* 483(7387): 100-103, 2012. DOI: 10.1038/nature10868
- 18 Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S: Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. *J Clin Oncol* 39(4): 273-284, 2021. DOI: 10.1200/JCO.20.02088
- 19 Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS: Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). *J Clin Oncol* 39(4): 285-294, 2021. DOI: 10.1200/JCO.20.01994
- 20 Kotani D, Takashima A, Kato T, Satoh T, Masuishi T, Komatsu Y, Shiozawa M, Esaki T, Izawa N, Takeuchi S, Bando H, Iwasa S, Hasegawa H, Yamaguchi T, Taniguchi H, Ushida Y, Oizaki T, Inoue C, Yoshino T: Safety and efficacy of encorafenib, binimetinib, and cetuximab for BRAFV600E-mutant metastatic colorectal cancer: results of the Japanese expanded access program. *Clin Colorectal Cancer* 23(2): 174-182.e6, 2024. DOI: 10.1016/j.clcc.2024.02.002
- 21 Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E, Elez E, Dekervel J, Ross P, Ruiz-Casado A, Graham J, Kato T, Ruffinelli JC, André T, Carrière Roussel E, Klauk I, Groc M, Vedovato JC, Tabernero J: ANCHOR CRC: Results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAF(V600E)-mutant metastatic colorectal cancer. *J Clin Oncol* 41(14): 2628-2637, 2023. DOI: 10.1200/JCO.22.01693
- 22 Kaiser J, Couzin-Frankel J: Cancer immunotherapy sweeps Nobel for medicine. *Science* 362(6410): 13-13, 2018. DOI: 10.1126/science.362.6410.13
- 23 Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN: Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. *J Clin Invest* 131(5): e145186, 2021. DOI: 10.1172/JCI145186
- 24 Vilar E, Gruber SB: Microsatellite instability in colorectal cancer-the stable evidence. *Nat Rev Clin Oncol* 7(3): 153-162, 2010. DOI: 10.1038/nrclinonc.2009.237
- 25 Zhong J, Sun Z, Li S, Yang L, Cao Y, Bao J: Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers. *Discov Oncol* 14(1): 94, 2023. DOI: 10.1007/s12672-023-00718-y
- 26 Aasebø KØ, Dragomir A, Sundström M, Mezheyski A, Edqvist PH, Eide GE, Ponten F, Pfeiffer P, Glimelius B, Sorbye H: Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. *Cancer Med* 8(7): 3623-3635, 2019. DOI: 10.1002/cam4.2205
- 27 Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fourchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zhong WY, Fogelman D, Marinello P, Andre T, KEYNOTE-177 Investigators: Pembrolizumab *versus* chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. *Lancet Oncol* 23(5): 659-670, 2022. DOI: 10.1016/S1470-2045(22)00197-8
- 28 Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ: Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). *J Immunother Cancer* 10(8): e005332, 2022. DOI: 10.1136/jitc-2022-005332
- 29 Nieuwenhuis L, Simons CCJM, Weijenberg MP, van den Brandt PA: Nut and peanut butter intake and the risk of colorectal cancer and its anatomical and molecular subtypes: the Netherlands Cohort Study. *Carcinogenesis* 41(10): 1368-1384, 2020. DOI: 10.1093/carcin/bgaa080
- 30 Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, Barker MA, Arnold S, McGivern A, Matsubara N, Tanaka N, Higuchi T, Young J, Jass JR, Leggett BA: BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. *Gut* 53(8): 1137-1144, 2004. DOI: 10.1136/gut.2003.037671
- 31 Leach JDG, Vlahov N, Tsantoulis P, Ridgway RA, Flanagan DJ, Gilroy K, Sphyris N, Vázquez EG, Vincent DF, Faller WJ, Hodder MC, Raven A, Fey S, Najumudeen AK, Strathdee D, Nixon C, Hughes M, Clark W, Shaw RS, CORT consortium, van Hooff SR, Huels DJ, Medema JP, Barry ST, Frame MC, Unciti-Broceta A, Leedham SJ, Inman GJ, Jackstadt R, Thompson BJ, Campbell AD, Tejpar S, Sansom OJ: Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis. *Nat Commun* 12(1): 3464, 2021. DOI: 10.1038/s41467-021-23717-5
- 32 Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR: Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. *Oncogene* 37(24): 3183-3199, 2018. DOI: 10.1038/s41388-018-0171-x
- 33 Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R, Cancer Genome Project: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell* 116(6): 855-867, 2004. DOI: 10.1016/s0092-8674(04)00215-6
- 34 Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. *Nat Rev Cancer* 17(2): 79-92, 2017. DOI: 10.1038/nrc.2016.126
- 35 Castro MP, Goldstein N: Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotherapeutic considerations. *J Immunother Cancer* 3: 58, 2015. DOI: 10.1186/s40425-015-0104-y
- 36 Kochi M, Hinoi T, Niitsu H, Miguchi M, Saito Y, Sada H, Sentani K, Sakamoto N, Oue N, Tashiro H, Sotomaru Y, Yasui W, Ohdan H: Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer. *Cancer Sci* 111(10): 3540-3549, 2020. DOI: 10.1111/cas.14558
- 37 Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M,

- Bergamo F, Zagonel V, Loupakis F, Fassan M: Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: a detailed clinical, pathologic, and molecular characterization. *Clin Cancer Res* 25(13): 3954-3961, 2019. DOI: 10.1158/1078-0432.CCR-19-0311
- 38 Müller MF, Ibrahim AE, Arends MJ: Molecular pathological classification of colorectal cancer. *Virchows Arch* 469(2): 125-134, 2016. DOI: 10.1007/s00428-016-1956-3
- 39 Pino MS, Chung DC: The chromosomal instability pathway in colon cancer. *Gastroenterology* 138(6): 2059-2072, 2010. DOI: 10.1053/j.gastro.2009.12.065
- 40 Avvaru AK, Saxena S, Sowpati DT, Mishra RK: MSDB: A comprehensive database of simple sequence repeats. *Genome Biol Evol* 9(6): 1797-1802, 2017. DOI: 10.1093/gbe/evx132
- 41 Nakamura Y: Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. *Front Med (Lausanne)* 6: 119, 2019. DOI: 10.3389/fmed.2019.00119
- 42 Kreidieh M, Mukherji D, Temraz S, Shamseddine A: Expanding the scope of immunotherapy in colorectal cancer: current clinical approaches and future directions. *Biomed Res Int* 2020: 9037217, 2020. DOI: 10.1155/2020/9037217
- 43 Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, Kaplan R, Quirke P, Seymour MT, Richman SD, Meijer GA, Ylstra B, Heideman DA, de Haan AF, Punt CJ, Koopman M: Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. *Clin Cancer Res* 20(20): 5322-5330, 2014. DOI: 10.1158/1078-0432.CCR-14-0332
- 44 Sahin IH, Klostergaard J: BRAF mutations as actionable targets: a paradigm shift in the management of colorectal cancer and novel avenues. *JCO Oncol Pract* 17(12): 723-730, 2021. DOI: 10.1200/OP.21.00160
- 45 Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S: The consensus molecular subtypes of colorectal cancer. *Nat Med* 21(11): 1350-1356, 2015. DOI: 10.1038/nm.3967
- 46 Loupakis F, Biason P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M: CK7 and consensus molecular subtypes as major prognosticators in (V600E)BRAF mutated metastatic colorectal cancer. *Br J Cancer* 121(7): 593-599, 2019. DOI: 10.1038/s41416-019-0560-0
- 47 Ros J, Rodríguez-Castells M, Saoudi N, Baraibar I, Salva F, Tabernero J, Élez E: Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers. *Expert Rev Anticancer Ther* 23(8): 797-806, 2023. DOI: 10.1080/14737140.2023.2236794
- 48 Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M: BRAF V600E mutant colorectal cancer subtypes based on gene expression. *Clin Cancer Res* 23: 104-115, 2017. DOI: 10.1158/1078-0432.CCR-16-0140
- 49 Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB: BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer. *Clin Cancer Res* 26(11): 2466-2476, 2020. DOI: 10.1158/1078-0432.CCR-19-3579
- 50 Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T: Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. *J Clin Oncol* 38(1): 11-19, 2020. DOI: 10.1200/JCO.19.02107
- 51 Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledezine JM, Maglinte GA, Kopetz S, André T: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol* 18(9): 1182-1191, 2017. DOI: 10.1016/S1470-2045(17)30422-9
- 52 André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ: Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. *Ann Oncol* 33(10): 1052-1060, 2022. DOI: 10.1016/j.annonc.2022.06.008
- 53 Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledezine JM, Overman MJ, Lonardi S: First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. *J Clin Oncol* 40(2): 161-170, 2022. DOI: 10.1200/JCO.21.01015
- 54 André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr, KEYNOTE-177 Investigators: Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. *N Engl J Med* 383(23): 2207-2218, 2020. DOI: 10.1056/NEJMoa2017699
- 55 Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, Yoshino T, Van Cutsem E, Yang P, Farooqui M, Le DT: Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab *versus* chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. *Lancet Oncol* 22(5): 665-677, 2021. DOI: 10.1016/S1470-2045(21)00064-4

- 56 Sahin IH, Goyal S, Pumpalova Y, Sonbol MB, Das S, Haraldsdottir S, Ahn D, Ciombor KK, Chen Z, Draper A, Berlin J, Bekaii-Saab T, Lesinski GB, El-Rayes BF, Wu C: Mismatch repair (MMR) gene alteration and BRAF V600E mutation are potential predictive biomarkers of immune checkpoint inhibitors in MMR-deficient colorectal cancer. *Oncologist* 26(8): 668-675, 2021. DOI: 10.1002/onco.13741
- 57 Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, De La Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Cela E, Yang Y, Lei M, Jin L, Lonardi S: Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. *JCO* 42(3_suppl): LBA768-LBA768, 2024. DOI: 10.1200/JCO.2024.42.3_suppl.LBA768
- 58 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr: PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 372(26): 2509-2520, 2015. DOI: 10.1056/NEJMoa1500596
- 59 Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson MD, Moss RA, Lin CS, Goldberg M, Andre T: Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. *JCO* 34(15_suppl): 3501-3501, 2016. DOI: 10.1200/JCO.2016.34.15_suppl.3501
- 60 Kim CW, Chon HJ, Kim C: Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer. *Cancers (Basel)* 13(19): 4906, 2021. DOI: 10.3390/cancers13194906
- 61 Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A: Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. *Proc Natl Acad Sci USA* 109(6): E353-E359, 2012. DOI: 10.1073/pnas.1105026109
- 62 Apte RS, Chen DS, Ferrara N: VEGF in signaling and disease: beyond discovery and development. *Cell* 176(6): 1248-1264, 2019. DOI: 10.1016/j.cell.2019.01.021
- 63 Bourhis M, Palle J, Galy-Fauroux I, Terme M: Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment. *Front Immunol* 12: 616837, 2021. DOI: 10.3389/fimmu.2021.616837
- 64 Khan KA, Kerbel RS: Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. *Nat Rev Clin Oncol* 15(5): 310-324, 2018. DOI: 10.1038/nrclinonc.2018.9
- 65 Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K: Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). *J Clin Oncol* 38(18): 2053-2061, 2020. DOI: 10.1200/JCO.19.03296
- 66 Damato A, Iachetta F, Antonuzzo L, Nasti G, Bergamo F, Bordonaro R, Maiello E, Zaniboni A, Tonini G, Romagnani A, Berselli A, Normanno N, Pinto C: Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). *BMC Cancer* 20(1): 822, 2020. DOI: 10.1186/s12885-020-07268-4
- 67 Fang C, Lin J, Zhang T, Luo J, Nie D, Li M, Hu X, Zheng Y, Huang X, Xiao Z: Metastatic colorectal cancer patient with microsatellite stability and BRAF(V600E) mutation showed a complete metabolic response to PD-1 blockade and bevacizumab: a case report. *Front Oncol* 11: 652394, 2021. DOI: 10.3389/fonc.2021.652394
- 68 Avery TY, Köhler N, Zeiser R, Brummer T, Ruess DA: Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. *Front Oncol* 12: 931774, 2022. DOI: 10.3389/fonc.2022.931774
- 69 Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghorri R, Ibrahim N, Moreno BH, Ribas A: Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. *Nat Med* 25(6): 941-946, 2019. DOI: 10.1038/s41591-019-0448-9
- 70 Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH Jr, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghorri R, Moreno BH, Ibrahim N, Hamid O: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. *Nat Med* 25(6): 936-940, 2019. DOI: 10.1038/s41591-019-0476-5
- 71 Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, Yan Y, Huang KC, Uyei A, McNally V, McArthur GA, Ascierto PA: Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 395(10240): 1835-1844, 2020. DOI: 10.1016/S0140-6736(20)30934-X
- 72 Zimmer L, Livingstone E, Krackhardt A, Schultz ES, Göppner D, Assaf C, Trebing D, Stelter K, Windemuth-Kieselbach C, Ugurel S, Schadendorf D: Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. *Eur J Cancer* 158: 72-84, 2021. DOI: 10.1016/j.ejca.2021.09.011
- 73 Corcoran R, Giannakis M, Allen J, Chen J, Pelka K, Chao S, Meyerhardt J, Enzinger A, Enzinger P, McCleary N, Yugelun M, Abrams T, Kanter K, Van Seventer E, Bradford W, Fetter I, Siravegna G, Tian J, Clark J, Ryan D, Hacohen N, Parikh A: SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients. *Ann Oncol* 31: S226-S227, 2020. DOI: 10.1016/j.annonc.2020.04.041
- 74 Elez E, Ros J, Tabernero J: Seeking therapeutic synergy in BRAF mutant colorectal cancer. *Nat Med* 29(2): 307-308, 2023. DOI: 10.1038/s41591-022-02192-5
- 75 Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E: Combined BRAF,

- EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. *Cancer Discov* 8(4): 428-443, 2018. DOI: 10.1158/2159-8290.CD-17-1226
- 76 Morris VK, Parseghian CM, Escano M, Johnson B, Raghav KPS, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, Shen JPY, Morelli MP, Tam A, Foo WC, Xiao L, Kopetz S: Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, *BRAF*^{V600E} metastatic colorectal cancer. *JCO* 40(4_suppl): 12-12, 2022. DOI: 10.1200/JCO.2022.40.4_suppl.012
 - 77 Morris VK, Guthrie KA, Kopetz S, Breakstone R, Karasic TB, Hu ZI, Colby S, Fakih M, Gholami S, Gold PJ, Philip PA: SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, *BRAF*^{V600E} metastatic and/or unresectable colorectal cancer. *JCO* 42(3_suppl): TPS234-TPS234, 2024. DOI: 10.1200/JCO.2024.42.3_suppl.TPS234
 - 78 Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P: Tumor microenvironment complexity and therapeutic implications at a glance. *Cell Commun Signal* 18(1): 59, 2020. DOI: 10.1186/s12964-020-0530-4
 - 79 Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF: Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nat Med* 24(5): 541-550, 2018. DOI: 10.1038/s41591-018-0014-x
 - 80 Leone RD, Powell JD: Metabolism of immune cells in cancer. *Nat Rev Cancer* 20(9): 516-531, 2020. DOI: 10.1038/s41568-020-0273-y
 - 81 Bai Z, Zhou Y, Ye Z, Xiong J, Lan H, Wang F: Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy. *Front Immunol* 12: 808964, 2022. DOI: 10.3389/fimmu.2021.808964
 - 82 Paijens ST, Vledder A, de Bruyn M, Nijman HW: Tumor-infiltrating lymphocytes in the immunotherapy era. *Cell Mol Immunol* 18(4): 842-859, 2021. DOI: 10.1038/s41423-020-00565-9
 - 83 Havel JJ, Chowell D, Chan TA: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. *Nat Rev Cancer* 19(3): 133-150, 2019. DOI: 10.1038/s41568-019-0116-x
 - 84 Fuchs TL, Sioson L, Sheen A, Jafari-Nejad K, Renaud CJ, Andrici J, Ahadi M, Chou A, Gill AJ: Assessment of tumor-infiltrating lymphocytes using international TILs working group (ITWG) system is a strong predictor of overall survival in colorectal carcinoma. *Am J Surg Pathol* 44(4): 536-544, 2020. DOI: 10.1097/PAS.0000000000001409
 - 85 Williams DS, Mouradov D, Newman MR, Amini E, Nickless DK, Fang CG, Palmieri M, Sakthianandeswaren A, Li S, Ward RL, Hawkins NJ, Skinner I, Jones I, Gibbs P, Sieber OM: Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation. *Mod Pathol* 33(7): 1420-1432, 2020. DOI: 10.1038/s41379-020-0496-1
 - 86 Nazemalhosseini-Mojarad E, Mohammadpour S, Torshizi Esafahani A, Gharib E, Larki P, Moradi A, Amin Porhoseingholi M, Asadzade Aghdai H, Kuppen PJK, Zali MR: Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features. *J Cell Physiol* 234: 4768-4777, 2019. DOI: 10.1002/jcp.27273
 - 87 Noshio K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. *J Pathol* 222(4): 350-366, 2010. DOI: 10.1002/path.2774
 - 88 Kwak Y, Koh J, Kim DW, Kang SB, Kim WH, Lee HS: Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. *Oncotarget* 7(49): 81778-81790, 2016. DOI: 10.18632/oncotarget.13207
 - 89 Cen S, Liu K, Zheng Y, Shan J, Jing C, Gao J, Pan H, Bai Z, Liu Z: BRAF mutation as a potential therapeutic target for checkpoint inhibitors: a comprehensive analysis of immune microenvironment in BRAF mutated colon cancer. *Front Cell Dev Biol* 9: 705060, 2021. DOI: 10.3389/fcell.2021.705060
 - 90 Digiacomo N, Bolzacchini E, Veronesi G, Cerutti R, Sahnane N, Pinotti G, Bregni M, Artale S, Verusio C, Crivelli F, Capella C, Sessa F, Furlan D: Neuroendocrine differentiation, microsatellite instability, and tumor-infiltrating lymphocytes in advanced colorectal cancer with BRAF mutation. *Clin Colorectal Cancer* 18(2): e251-e260, 2019. DOI: 10.1016/j.clcc.2018.12.003
 - 91 Wang H, Tian T, Zhang J: Tumor-associated macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis. *Int J Mol Sci* 22(16): 8470, 2021. DOI: 10.3390/ijms22168470
 - 92 Aasebø K, Bruun J, Bergsland CH, Nunes L, Eide GE, Pfeiffer P, Dahl O, Glimelius B, Lothe RA, Sorbye H: Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. *Br J Cancer* 126(1): 48-56, 2022. DOI: 10.1038/s41416-021-01586-5
 - 93 Zhi J, Jia XJ, Yan J, Wang HC, Feng B, Xing HY, Jia YT: BRAF(V600E) mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs. *World J Gastrointest Oncol* 13(12): 2129-2148, 2021. DOI: 10.4251/wjgo.v13.i12.2129
 - 94 Kornepati AVR, Vadlamudi RK, Curiel TJ: Programmed death ligand 1 signals in cancer cells. *Nat Rev Cancer* 22(3): 174-189, 2022. DOI: 10.1038/s41568-021-00431-4
 - 95 Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. *Mol Cancer* 21(1): 28, 2022. DOI: 10.1186/s12943-021-01489-2
 - 96 Patel SP, Kurzrock R: PD-L1 expression as a predictive biomarker in cancer immunotherapy. *Mol Cancer Ther* 14(4): 847-856, 2015. DOI: 10.1158/1535-7163.MCT-14-0983
 - 97 Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthi S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 366(26): 2455-2465, 2012. DOI: 10.1056/NEJMoa1200694
 - 98 Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF,

- Marshall JL, Philip PA, Lenz HJ: Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. *Mol Cancer Res* 16(5): 805-812, 2018. DOI: 10.1158/1541-7786.MCR-17-0735
- 99 Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M: PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. *Mod Pathol* 29(9): 1104-1112, 2016. DOI: 10.1038/modpathol.2016.95
- 100 Sudoyo AW, Kurniawan AN, Kusumo GD, Putra TP, Rexana FA, Yunus M, Budiayati AD, Kurniawan D, Utama A, Utomo AR: Increased CD8 tumor infiltrating lymphocytes in colorectal cancer microenvironment supports an adaptive immune resistance mechanism of PD-L1 expression. *Asian Pac J Cancer Prev* 20(11): 3421-3427, 2019. DOI: 10.31557/APJCP.2019.20.11.3421
- 101 Inaguma S, Lasota J, Wang Z, Felisiak-Golabek A, Ikeda H, Miettinen M: Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. *Mod Pathol* 30(2): 278-285, 2017. DOI: 10.1038/modpathol.2016.185
- 102 Siraj AK, Parvathareddy SK, Annaiyappanaidu P, Haqawi W, Al-Rasheed M, AlManea HM, AlHussaini HF, Al-Dayel F, Al-Kuraya KS: PD-L1 expression is associated with deficient mismatch repair and poor prognosis in Middle Eastern colorectal cancers. *J Pers Med* 11(2): 73, 2021. DOI: 10.3390/jpm11020073
- 103 Carballal S, Balaguer F, IJseert JEG: Serrated polyposis syndrome; epidemiology and management. *Best Pract Res Clin Gastroenterol* 58-59: 101791, 2022. DOI: 10.1016/j.bpg.2022.101791
- 104 Ma R, Liu Y, Che X, Li C, Wen T, Hou K, Qu X: Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3. *Cancer Lett* 527: 127-139, 2022. DOI: 10.1016/j.canlet.2021.12.017
- 105 Feng D, Chen Z, He X, Huang S, Zhang Z: Loss of tumor intrinsic PD-L1 confers resistance to drug-induced apoptosis in human colon cancer. *Neoplasia* 68(01): 144-153, 2021. DOI: 10.4149/neo_2020_200531N589
- 106 Feng D, Qin B, Pal K, Sun L, Dutta S, Dong H, Liu X, Mukhopadhyay D, Huang S, Sinicrope FA: BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. *Oncogene* 38(41): 6752-6766, 2019. DOI: 10.1038/s41388-019-0919-y
- 107 Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH: Tertiary lymphoid structures in the era of cancer immunotherapy. *Nat Rev Cancer* 19(6): 307-325, 2019. DOI: 10.1038/s41568-019-0144-6
- 108 Schumacher TN, Thommen DS: Tertiary lymphoid structures in cancer. *Science* 375(6576): eabf9419, 2022. DOI: 10.1126/science.abf9419
- 109 Posch F, Silina K, Leibl S, Mündlein A, Moch H, Siebenhüner A, Samaras P, Riedl J, Stotz M, Szkandera J, Stöger H, Pichler M, Stupp R, van den Broek M, Schraml P, Gerger A, Petrausch U, Winder T: Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. *Oncoimmunology* 7(2): e1378844, 2017. DOI: 10.1080/2162402X.2017.1378844
- 110 Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK: SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. *Future Oncol* 20(11): 653-663, 2024. DOI: 10.2217/fon-2022-1249
- 111 Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, Randon G, Vivancos A, Smits R, Graus D, Perez-Lopez R, Cremolini C, Lonardi S, Pietrantonio F, Dienstmann R, Tabernero J, Toledo RA: RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer. *Nat Med* 28(10): 2162-2170, 2022. DOI: 10.1038/s41591-022-01976-z
- 112 Li Y, Du Y, Xue C, Wu P, Du N, Zhu G, Xu H, Zhu Z: Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis. *BMC Gastroenterol* 22(1): 431, 2022. DOI: 10.1186/s12876-022-02511-7
- 113 Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martín Á, Antista M, Toledo R, Martinelli E, Pietrantonio F, Boccaccino A, Cremolini C, Dienstmann R, Tabernero J, Vivancos A, Elez E: Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. *Ann Oncol* 34(6): 543-552, 2023. DOI: 10.1016/j.annonc.2023.02.016
- 114 Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Grothey A, Van Cutsem E, Wasan HS, Yaeger R, Yoshino T, Donahue AC, Golden A, Gollerkeri A, Zhu Z, Tabernero J: Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. *JCO* 39(15_suppl): 3513-3513, 2021. DOI: 10.1200/JCO.2021.39.15_suppl.3513
- 115 Zhang R, Wang Z, Wang H, Li L, Dong L, Ding L, Li Q, Zhu L, Zhang T, Zhu Y, Ding K: CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. *Biomol Biomed*, 2024. DOI: 10.17305/bb.2024.10397

Received September 4, 2024

Revised September 26, 2024

Accepted September 30, 2024